Journal
JOURNAL OF CONTROLLED RELEASE
Volume 288, Issue -, Pages 239-263Publisher
ELSEVIER
DOI: 10.1016/j.jconrel.2018.09.010
Keywords
Cancer Immunotherapy; Nanoparticles; Antigenic Peptides; Oligodeoxynucleotides; Immunomodulatory siRNA; Antigenic pDNA; Immune check point inhibitor
Funding
- Canadian Institutes of Health Research (CIHR)
- National Institutes of Health
- Natural Sciences and Engineering Research Council of Canada
- Canada Foundation for Innovation
- CIHR New Investigator Award
- Angiotech Professorship in Drug Delivery
- Prostate Cancer Foundation
Ask authors/readers for more resources
Cancer immunotherapy aimed at boosting cancer-specific immunoresponses to eradicate tumor cells has evolved as a new treatment modality. Nanoparticles incorporating antigens and immunomodulatory agents can activate immune cells and modulate the tumor microenvironment to enhance anti-tumor immunity. The nanotechnology approach has been demonstrated to be superior to standard formulations in in-vivo settings. In this article, we focus on recent advances made within the last 5 years in nanoparticle-based cancer immunotherapy, including peptide- and nucleic acid-based nanovaccines, nanomedicines containing an immunoadjuvant to activate antitumor immunity, nanoparticle delivery of immune checkpoint inhibitors and the combination of the above approaches. Encouraging results and new emerging nanotechnologies in drug delivery promise the continuous growth of this field and ultimately clinical translation of enhanced immunotherapy of cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available